What if it were possible to attack what cancers have in common?

João Forjaz de Lacerda works at three institutions in Lisbon, focusing on hematology and innovative cancer treatments. His research includes developing CAR-T therapies targeting malignancy markers, aiming for fewer side effects. Recent advancements in hematology have led to new targeted therapies, improving cancer treatment outcomes. Lacerda's lab is exploring a specific marker found in over 90% of tumors, with promising preliminary results. Further studies are needed to assess efficacy and safety before clinical application.